News

The biomarker MR-proADM improves risk prediction in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and is associated with greater disease…

Clearing established amyloid deposits from the heart — not merely slowing their formation — is the defining unmet need in ATTR cardiac amyloidosis. This report maps…

AbstractTransthyretin amyloidosis (ATTR) is a rapidly evolving disease with a rising prevalence and improving prognosis. With an increasing number of patients…

Study OverviewBrief SummaryThe goal of this study is to learn whether PET-CT imaging using evuzamitide can help diagnose transthyretin cardiac amyloidosis (ATTR-CA…

Patients who had a delayed diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) had higher healthcare utilization, which resulted in higher pharmacy spending…

Carpal tunnel syndrome (CTS) in both wrists may be a red flag of transthyretin amyloidosis (ATTR), including hereditary transthyretin amyloidosis with…

The ATTR amyloidosis pipeline has expanded far beyond patisiran, with RNA interference, CRISPR gene editing, monoclonal antibodies, and next-generation stabilizers…

Background Hereditary transthyretin amyloidosis (hATTR) manifests as cardiomyopathy and/or polyneuropathy. The V142I variant predominantly causes cardiac disease in…

Long-term use of approved therapy safely extends patient survival, data showStarting Attruby (acoramidis) early and taking it continuously helps adults with…

A new study demonstrated that naturally occurring antibodies targeting transthyretin (TTR) are present in the serum of both healthy individuals and patients with…